Modulation of Splenocytes in Cell Therapy for Traumatic Brain Injury

A method for obtaining cells having a desired potency for one or more of (1) preserving splenic mass in a traumatic brain injury, (2) increasing splenocyte proliferation in the spleen, (3) increasing CD4+ and CD8+ T-cells, (4) increasing IL-10 and/or IL-4, (5) modulating macrophage activation, the method comprising selecting cells that have the desired potency, the cells being non-embryonic, non-germ cells that express one or more of oct4, telomerase, rex-1, or rox-1 and/or can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

A method for establishing a therapeutic regimen in a subject with a traumatic brain injury, the method comprising (A) establishing a baseline in the subject for any of the following parameters:

• (1) splenic mass, (2) CD4+ lymphocytes, (3) CD8+ lymphocytes, (4) IL-10, (5) IL-4, (6) M1 macrophages, (7) M2 macrophages, and (8) T-regulatory cells (B) administering cells in an amount and for a time sufficient to allow the cells to interact with resident splenocytes in the spleen;
• and (C) assaying the subject for one or more of (1)-(8), wherein the cells that are administered are non-embryonic non-germ cells that express one or more of oct4, telomerase, rex-1 or rox-1 and/or can differentiate into cell type of at least two of endodermal, ectodermal, and mesodermal germ layers.

A method for optimizing a route of administration for cell therapy in a subject with a traumatic brain injury, the method comprising, ascertaining splenic involvement by measuring splenic mass, and, where splenic mass is decreased, administering the cells by a route in which the administered cells interact with splenocytes in the subject's spleen.

A method to determine the use of stem cell therapy in a subject with a traumatic brain injury, the method comprising ascertaining splenic involvement in the subject and, where there is splenic involvement, administering the cells.